J Rheum Dis 2012; 19(2): 91-94
Published online April 30, 2012
© Korean College of Rheumatology
Correspondence to : Sung Hwan Park
Hematologic malignancies and lymphoproliferative disorders have been reported after using tumor necrosis factor-a inhibitor in patients suffering from spondyloarthropathy. Previously reported cases were treated by using infliximab and etanercept. Usually, it takes approximately several months for leukemia or lymphoproliferative disorders to occur after the application of those agents. However, we report a case of acute myeloid leukemia that developed after short term usage of adalimumab in a patient suffering from psoriatic arthritis.
Keywords Psoriatic arthritis, Acute myeloid leukemia, Adalimumab
J Rheum Dis 2012; 19(2): 91-94
Published online April 30, 2012
Copyright © Korean College of Rheumatology.
Hong Ki Min1, Jae Ho Lee1, Hae Min Lee1, Eunsil Koh1, Ju Yeon Heo1, Jun-Ki Min2, Sung Hwan Park1
Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, School of Medicine, The Catholic University of Korea1, Seoul, Bucheon St. Mary's Hospital, School of Medicine, The Catholic University of Korea2, Bucheon, Korea
Correspondence to:Sung Hwan Park
Hematologic malignancies and lymphoproliferative disorders have been reported after using tumor necrosis factor-a inhibitor in patients suffering from spondyloarthropathy. Previously reported cases were treated by using infliximab and etanercept. Usually, it takes approximately several months for leukemia or lymphoproliferative disorders to occur after the application of those agents. However, we report a case of acute myeloid leukemia that developed after short term usage of adalimumab in a patient suffering from psoriatic arthritis.
Keywords: Psoriatic arthritis, Acute myeloid leukemia, Adalimumab
Su Nam Lee, Jun Ki Min, Joon Hur, Dong Hwi Kim, Yong Hyun Kim,Soon Seog Kwon, Heejeong Lee
J Rheum Dis 2011; 18(3): 216-219Roshan Subedi, M.D., Afrah Misbah, M.D., Adnan Al Najada, M.D., Anthony James Ocon, M.D., Ph.D.
J Rheum Dis -0001; ():Ji Hyoun Kim, M.D., Sang Wan Chung, M.D., Ph.D., Yun Jong Lee, M.D., Ph.D.
J Rheum Dis 2024; 31(3): 178-181